[Exercise and nicotinic acid delayed action drug Enduracin: application in outpatient rehabilitation of patients with ischemic heart disease].
OBJECTIVE
To evaluate efficacy of combined use of moderate exercise and nicotinic acid drug enduracin in patients with coronary heart disease (CHD) with moderate dyslipidemia (DE).


METHODS
The effects of exercise therapy alone, enduracin alone and their combination on physical performance (PP), hemodynamics, blood lipid spectrum and clinical course of CHD were studied in 93 CHD patients with moderate DE. The results were evaluated clinically after 1-year treatment.


RESULTS
Combined used of exercise and enduracin in CHD patients showed its efficacy manifesting in improvement of PP, hemodynamics at rest and exercise test, left ventricular systolic function, clinical course, reduction of DE. Enduracin + exercise appeared more efficient than their use in monotherapy. Enduracin monotherapy had a positive action on PP, arterial pressure and anginal attacks frequency.


CONCLUSIONS
Enduracin is recommended as monotherapy and in combination with moderate exercise in outpatient rehabilitation and secondary prophylaxis of CHD patients with moderate dyslipidemia and angina pectoris to relieve myocardial ischemia under exercise, to raise PP, improve lipid composition of blood and prevent maladaptive left ventricular remodeling.
Oganov
R G
RG
Aronov
D M
DM
Krasnitskiĭ
V B
VB
Perova
N V
NV
Olfer'ev
A M
AM
Smolenskiĭ
A V
AV
Novikov
H K
HK
Vygodin
V A
VA
D000553:Ambulatory Care; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000534:rehabilitation*; D009525:Niacin / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D009525:Niacin